Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Kouzy, R, Rooney, M, Cha, E, Vinjamuri, S, Wu, H, Kouzi, ZE, Mohamad, O, Sims, TT , Weil, CR, Taku, N, Lin, LL, Jhingran, A, Eifel, PJ, Joyner, MM, Colbert, LE, Klopp, AH . AI based sentiment analysis of online discussions related to cervical brachytherapy. Technical Innovations and Patient Support
— 2025cited by 0position: selected
Rajan, SS, Ning, M, Jacobson, M, Simiele, SJ, Bruno, TL, Kouzy, R, Court, K, Cisneros-Napravnik, T, Yu, H, Stafford, J, Kim, Y, Mathew, GG, Cordova, RA, Domingo, M, Jhingran, A, Lin, LL, Joyner, MM, Sims, TT , Colbert, LE, Venkatesan, AM, Klopp, AH . Iterative intraoperative 3T MRI (iMRI)-guided bra
— 2025cited by 0position: selected
Sims, TT , Court, K, El Alam, MB, Ramatlho, P, Ketlametswe, R, Ning, M, Robertson, ES, Schmeler, KM, Colbert, LE, Klopp, AH, Grover, S . Cervical and Tumor-Associated Microbiomes in Botswana Women With and Without HIV With Carcinoma of the Cervix Before and After Definitive Chemoradiation. JCO Globa
— 2025cited by 0position: selected
Kim, M, Asare, A, Dockery, JL, Hameed, N, Sims, TT . Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma. Gynecologic Oncology Reports 60, 2025. e-Pub 2025. PMID: 40687920.
— 2025cited by 0position: selected
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy
Son, J, Cain, K, Marten, CA, Dwyer, KW, Sims, TT , Taylor, JS . Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer. Gynecologic Oncology Reports 56, 2024. e-Pub 2024. PMID: 39431057.
— 2024cited by 0position: selected
Wilke RN, Liu J, Westin SN, Sims TT , Fellman BM, Pham M, Rangel K, Sey E, Rauh-Hain JA, Lu KH, Sood AK, Fleming ND . The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy.
— 2024cited by 0position: selected
Manzar GS, Alam MBE, Lynn EJ, Karpinets TV, Harris T, Lo D, Yoshida-Court K, Napravnik TC, Sammouri J, Lin D, Andring LM, Bronk J, Wu X, Sims TT , Mathew G, Schmeler KM, Eifel PJ, Jhingran A, Lin LL, Joyner MM, Zhang J, Futreal A, Klopp AH, Colbert LE . Exploratory analysis of the cervix tumoral HPV
— 2024cited by 0position: selected
Eyada, M, Fellman, B, Patel, S, Michael, V, Soliman, PT, Sims, TT , How, JA, Jazaeri, AA, Fleming, N, Ramondetta, LM, Westin, SN . Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
— 2024cited by 0position: selected
Eyada, M, Michael, V, Fellman, B, Patel, S, Soliman, PT, How, JA, Jazaeri, AA, Fleming, N, Sood, AK, Westin, SN, Sims, TT . Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
— 2024cited by 0position: selected
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring
The insulin receptor regulates the persistence of mechanical nociceptive sensitization in flies and mice.
Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.
Cancer-associated
<i>Lactobacillus iners</i>
are genetically distinct and associated with chemoradiation resistance in cervical cancer
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation
Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy